Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Sunday, April 22, 2012
Gary Osborn and Apothecure are Scheduled to Plead Guilty in Compounding case Charging Misbranded Drug Violations
On April 18, 2012, the United States, Gary D. Osborn and Apothecure filed a plea agreement and factual resume in the Northern District of Texas. Pursuant to the plea agreement, Osborn and Apothecure have agreed to plead guilty to the two-count information, charging violations of 21 U.S.C. Section 331(a), 352(a) and 333(a)(1)--all criminal, class A misdemeanors. ApothéCure and Gary D. Osborn are admitting that they introduced into interstate commerce a misbranded drug with a false and misleading label. The defendants face up to a year of imprisonment. Most likely, the defendants will receive probation and be ordered to pay a fine of $100,000. The parties, while not agreement on the amount of the fine, have agreed that $100,000 would be a reasonable fine in this case. Nevertheless, the United States' position is that the maximum fine can be imposed up to $250,000 for each count in the information. The defendants have also agreed to pay restitution to the victims or community, which is mandatory under federal law. The rearraignment and entry of the plea of guilty are scheduled for April 24, 2012, at 10:30 a.m.
Subscribe to:
Post Comments (Atom)
1 comment:
Cool article. If you ever have any clients that run into legal issues with the DEA, consider referring them to a DEA defense lawyer
Post a Comment